Prostate Cancer


Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (February 18, 2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs... Continue Reading

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide... Continue Reading

SBRT Offers Prostate Cancer Patients High Cancer Control and Low Toxicity in Fewer Treatments (September 28, 2016)

High dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity and excellent cancer control... Continue Reading

Pass it On: It’s National Prostate Cancer Awareness Month (September 5, 2016)

Prostate cancer is the most common type of cancer in men other than skin cancer, and the second leading cause of death.  The American Cancer Society estimates that in 2015 there will be approximately... Continue Reading

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (August 15, 2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently... Continue Reading

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer (August 10, 2016)

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published... Continue Reading

Study Suggests Men with Metastatic Prostate Cancer Should Be Tested for Inherited Mutations (July 14, 2016)

Ever since inherited mutations in BRCA genes were first linked to breast and ovarian cancer two decades ago, this information has been used as a way to help empower women. Those who have the mutations... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Addition of Radiation Improves Survival in High-Risk Prostate Cancer (May 18, 2016)

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were... Continue Reading

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers (May 17, 2016)

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently... Continue Reading

Protons & Prostate Cancer Treatment (April 21, 2016)

By John Leifer There are few things more mind-numbing than nuclear physics. Fortunately, you don’t have to be a physicist to understand proton therapy. Your goal, after all, is not to understand sub-atomic... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (April 19, 2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer. ... Continue Reading

Shorter, Intensive Radiation Can Be Recommended in Early Prostate Cancer (April 14, 2016)

DURHAM, N.C. –- Giving early-stage prostate cancer patients a slightly higher daily dose of radiation can cut more than two weeks from the current treatment regimen without compromising cancer control,... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (March 14, 2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy... Continue Reading

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer (March 9, 2016)

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS